IDWeek (2019), 2–6 October 2019, Washington DC

18 October 2019. Related: Conference reports, Conference index, IDWeek 2019.

Introduction

Simon Collins, HIV i-Base

This year the annual Infectious Diseases conference (IDWeek 2019) was held in Washington DC.

Although i-Base wasn’t able to attend this meeting, some of the studies reported by the US activist website natap.org will be of interested to UK readers.

It is likely that some of these studies might also be presented at the European AIDS Conference that is being help in Basel next month that i-Base will report from.

Unfortunately IDWeek doesn’t publish much of their conference available online. NATAP however publishes make slides online with approximately 70 presentations either reported as slides or summary reports by Mark Mascolini.
http://natap.org/2019/IDWeek/IDWeek.htm

Articles in the issue of HTB include a selection of the 30 summary reports.

• HIV suppression and safety with ibalizumab at 48 weeks in expanded access

• Oral cabotegravir and rilpivirine is durable for 5.5 years in LATTE study

• Dolutegravir plus rilpivirine had good virologic, safety record in clinics before single tablet available

• Switching from TDF to TAF linked to higher BMI and cardio risk

• Possible higher diabetes risk with raltegravir or PIs than NNRTIs

• Fostemsavir interaction study flags strong CYP3A inducers, statins, oral contraceptives

• Over half of mostly black US HIV group has NAFLD – and many have NASH

• People taking more medications and women have higher fall risk in older HIV group

• No link between raltegravir and adverse birth outcomes in analysis in 2550 women

• PrEP linked to lower HIV incidence in US, independent of TasP